{"nct_id":"NCT02961881","title":"A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma","status":"COMPLETED","status_verified_date":"2023-05","start_date":"2017-09-18","start_date_type":"ACTUAL","primary_completion_date":"2021-09-02","primary_completion_date_type":"ACTUAL","completion_date":"2021-09-02","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["AMGN"]}